A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

What Was Tested

This registered phase 3 trial tested Tirzepatide and Eloralintide.

Participation in the study will last about 2 years.

It had two arms (groups): EloraTZP (experimental) and Tirzepatide (experimental).

Participants will receive EloraTZP subcutaneously (SC).

Participants will receive tirzepatide SC.

The registry classes the interventions as drug.

Who Took Part

The registry lists 1000 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have type 2 diabetes. Have a BMI of ≥27 kg/m2 at screening.

The full record lists 4 inclusion and 15 exclusion criteria; among the exclusions: have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening); have type 1 diabetes; have taken any of the following within 90 days prior to screening.

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

As a double-blind Tirzepatide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2026-11 with completion listed for 2029-10.

It ran at 75 sites in United States (25), Romania (10), Spain (9), China (7), Brazil (6) and Germany (6).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Percent Change from Baseline in Body Weight (time frame: Baseline, Week 100).

It also tracked 21 secondary outcomes, for example Change from Baseline in Waist Circumference, Change from Baseline in Hemoglobin A1c (HbA1c), Change from Baseline in Systolic Blood Pressure, Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP), Percent Change from Baseline in Total Body Fat Mass and Change from Baseline in Body Mass Index (BMI).

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Tirzepatide and Eloralintide in 1000 people.

With 1000 participants it is a large trial for this field.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page and the Eloralintide compound page, all human trials.